Metabolic Syndrome, Insulin Resistance and Adiponectin Level in Patients with
Chronic Hepatitis C

download Full Article (PDF file)

Mircea Grigorescu1, Corina Radu1, Dana Crişan1, Mircea Dan Grigorescu1, Alexandru Şerban2, Dana Neculoiu3, Margareta Rusu2, Monica Acalovschi1

1) 3rd Medical Clinic, University of Medicine and Pharmacy, Cluj-Napoca;
2) Emergency Universitary Hospital, Cluj-Napoca;
3) Emergency County Hospital, Brasov, Romania


Aims. To assess insulin resistance and adiponectin profile in patients with chronic hepatitis C (CHC), according to the presence or absence of metabolic syndrome (MS).

Patients and methods. One hundred and fifty-two patients with histologically proven CHC, genotype I were prospectively studied. Parameters of MS according to the IDF criteria were evaluated. Insulin resistance was established by homeostasis model assessment (HOMA-IR]. An index = 2.0 was designated as IR and = 4 as prediabetic state. Serum adiponectin levels were measured by ELISA.

Results. MS was found in 61.48% of cases. HOMA-IR was significantly higher in patients with CHC and MS vs those without MS (7.88±1.11 vs 4.29 ±0.5, p=0.023]. Adiponectin levels had an inverse behaviour (9,946.1 ±5,811 ng/ml vs 13,215.5 ± 815.5 ng/ml, p< 0.001]. By multiple linear regression analysis the independent predictors associated with HOMA-IR = 4 in patients with CHC and MS were visceral obesity, adiponectin levels, activity and degree of steatosis. Only visceral obesity and HOMA-IR were independently associated with adiponectin. A significant negative correlation was established between adiponectin and insulin (r = - 0.169, p=0.003] and between adiponectin and HOMA-IR (r = - 0.188, p=0.02].

Conclusions. CHC with MS was associated with a higher insulin resistance and lower adiponectin level. Adiponectin level and insulin resistance were significantly correlated.

Key words
Chronic hepatitis C - metabolic syndrome - insulin resistance - serum adiponectin